Trial Profile
A One-Year, Multicenter, Observational, Follow-up Safety Study in Subjects Previously Implanted With VC-01™ Combination Product
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors ViaCyte
- 01 May 2023 Planned End Date changed from 1 Nov 2023 to 1 Mar 2024.
- 01 May 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Mar 2024.
- 01 May 2023 Status changed from recruiting to active, no longer recruiting.